Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2010-03-22 Annual Report
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Annual Report 2009
Annual Report Classification · 100% confidence The document is titled 'Medivirs årsredovisning 2009' (Medivir Annual Report 2009). It contains a comprehensive overview of the company's performance, management discussion, financial highlights, and strategic outlook for the fiscal year 2009. It is clearly the full annual report document, not an announcement or summary. FY 2009
2010-03-22 Swedish
Annual Report 2009
Annual Report Classification · 100% confidence The document is explicitly titled 'Medivir's Annual Report for 2009' and contains standard annual report sections such as the CEO's statement, Report of the Directors, Income Statement, Balance Sheet, and Audit Report. It is a comprehensive financial document covering the full fiscal year, not an announcement or a summary. FY 2009
2010-03-22 English
Report Publication Announcement 2010
Report Publication Announcement Classification · 95% confidence The document is titled "Press Release, 12 March 2010" and provides a "Summary of the R&D update held earlier today." It explicitly states that the presentation from this research & development update is available on the company website. The content details R&D focus, project portfolio status, and a product launch update (Xerclear™). Since this is a summary announcement about an event (R&D update/presentation) and directs the reader to the website for the full presentation, it fits the definition of announcing the publication or availability of information related to investor relations/events, rather than being the full presentation itself (IP) or a formal earnings release (ER). Given the context of providing an update summary and pointing to the presentation, the most fitting category is Report Publication Announcement (RPA), as it announces the availability of the R&D update presentation materials. It is too specific for the general RNS fallback.
2010-03-12 English
Report Publication Announcement 2010
Report Publication Announcement Classification · 95% confidence The document is titled "Press Release, 12 March 2010" and provides a "Summary of the R&D update held earlier today." It explicitly states that the presentation from this research & development update is available on the company website. The content details R&D focus, project portfolio status, and a product launch update (Xerclear™). Since this is a summary announcement about an event (R&D update/presentation) and directs the reader to the website for the full presentation, it fits the definition of announcing the publication or availability of information related to investor relations/events, rather than being the full presentation itself (IP) or a formal earnings release (ER). Given the context of providing an update summary and pointing to the presentation, the most fitting category is Report Publication Announcement (RPA), as it announces the availability of the R&D update presentation materials. It is too specific for the general RNS fallback.
2010-03-12 Swedish
M&A Activity 2010
M&A Activity Classification · 95% confidence The document is a press release dated March 11, 2010, announcing a licensing agreement between Medivir and Daewoong Pharmaceutical for the drug MIV-210. This announcement details a transaction involving the transfer of clinical development rights and marketing rights for specific territories (South Korea, Japan, China). This type of corporate action, specifically related to licensing, development rights, or strategic partnerships in the pharmaceutical sector, falls under the category of M&A Activity or a significant corporate transaction. Given the provided definitions, 'M&A Activity (Code: TAR)' is the most appropriate classification for a major licensing deal that transfers development and marketing rights, as it represents a significant strategic transaction affecting the company's assets and future revenue streams, similar to a merger or takeover proposal in scope of impact. It is not an Earnings Release (ER), Interim Report (IR), Annual Report (10-K), or a simple management change (MANG). It is a specific corporate transaction announcement.
2010-03-11 Swedish
Regulatory Filings 2010
Regulatory Filings Classification · 96% confidence The document is a press release dated March 11, 2010, announcing a license agreement between Medivir and Daewoong Pharmaceutical for the drug MIV-210. This announcement details a transaction involving the transfer of rights, financial terms (upfront, milestones, royalties), and future development plans. This type of corporate action, specifically related to licensing, development rights, and potential future revenue streams from a drug asset, falls under the category of significant corporate transactions or financing activities. Since it is not a standard regulatory filing (like 10-K or IR), nor a management change (MANG), nor a dividend announcement (DIV), it best fits the 'Capital/Financing Update' (CAP) category as it concerns the commercialization and financial structuring of a key asset. It is not a merger/takeover (TAR), but a licensing deal which impacts capital structure and future earnings potential.
2010-03-11 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.